| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Clinical and Translational Research |
| Article Title |
Effects of targeted-edited oncogenic insulin-like growth factor-1 receptor with specific-sgRNA on biological behaviors of HepG2 cells
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Min Yao, Yin Cai, Zhi-Jun Wu, Ping Zhou, Wen-Li Sai, De-Feng Wang, Li Wang and Deng-Fu Yao |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China |
81873915 |
| National Natural Science Foundation of China |
31872738 |
| National Natural Science Foundation of China |
81673241 |
| Key Plan of Nantong S & T Developmen |
MS12020021 |
| Program of Medical School S & T of Nantong University |
2018YFC0116902 |
|
| Corresponding Author |
Deng-Fu Yao, MD, PhD, Director, Full Professor, Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, 20 West Temple Road, Nantong 226001, Jiangsu Province, China. E-mail: yaodf@ahnmc.com. Tel: +086-513-85052523, Nantong 226001, China. yaodf@ahnmc.com |
| Key Words |
Hepatocellular carcinoma; Insulin-like growth factor-1 receptor; Synergistic effects; Multidrug resistance; Growth inhibition; Biological behaviors |
| Core Tip |
Abnormal expression of insulin-like growth factor-1 receptor (IGF-1R) was associated with hepatocellular carcinoma (HCC). IGF-1R level was significantly higher in HCC more than that in their noncancerous tissues. Circulating IGF-1R continued to increase from benign liver disease to HCC. Down-regulating expression of IGF-1R with a specific sgRNA was markedly affected on biological behaviors of HCC cells, including inhibiting cell proliferation, decreasing cell migration or invasion potential, increasing cell apoptosis and enhancing cell susceptibility to anti-tumor drugs and indicated that oncogenic IGF-1R should be a promising targeted-molecule for HCC therapy. |
| Publish Date |
2022-09-27 13:00 |
| Citation |
Yao M, Cai Y, Wu ZJ, Zhou P, Sai WL, Wang DF, Wang L, Yao DF. Effects of targeted-edited oncogenic insulin-like growth factor-1 receptor with specific-sgRNA on biological behaviors of HepG2 cells. World J Clin Cases 2022; 10(28): 10017-10030 |
| URL |
https://www.wjgnet.com/2307-8960/full/v10/i28/10017.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v10.i28.10017 |
